News
IL-17 inhibitors are approved for axial spondyloarthritis and psoriatic arthritis, but their effectiveness in heavily ...
In recently reported case studies, nemolizumab, approved for two indications associated with itch, has been reported to be ...
Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...
17h
MedPage Today on MSNWhat Happened to Our Brains During the Pandemic?"Longer follow-ups after the pandemic are needed to investigate persistent brain aging effects and their long-term ...
The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump ...
Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, & Head of Development starting Aug 2025.
Explore more
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development ...
Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.
Bristol Myers Squibb has appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development.
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer (CMO), persuading Cristian Massacesi, M.D.
Bristol Myers Squibb has appointed Dr Cristian Massacesi as Executive Vice President, Chief Medical Officer and Head of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results